Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scope Fluidics Spolka AkcyjnaWAR:SCP +0.88%42 Debt-to-Equity is 0.02 as of Mar. 2026, which is 33% below its 10-year median of 0.03. GuruFocus rates WAR:SCP with a GF Score™ of 42/100 and a GF Value™ of zł126.08 (Fairly Valued). The stock has 4 warning signs investors should review. Among 180 Medical Diagnostics & Research companies, Scope Fluidics Spolka Akcyjna ranks better than 91.67% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's Debt-to-Equity or its related term are showing as below:
WAR:SCP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 4.4
Current: 0.02
During the past 10 years, the highest Debt-to-Equity Ratio of Scope Fluidics Spolka Akcyjna was 4.40. The lowest was 0.00. And the median was 0.03.
WAR:SCP's Debt-to-Equity is ranked better than 91.67% of 180
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.275
vs WAR:SCP: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Scope Fluidics Spolka Akcyjna Debt-to-Equity Related Terms
Scope Fluidics Spolka Akcyjna Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCP vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. This is 33% below median its historical median of 0.03. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #15 out of 180 companies in the Medical Diagnostics & Research industry, placing it in the top 8.3%.
Is Scope Fluidics Spolka Akcyjna's Debt-to-Equity too high?
Scope Fluidics Spolka Akcyjna's current Debt-to-Equity of 0.02 is 33% below median its 10-year median of 0.03. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.28. Scope Fluidics Spolka Akcyjna's value of 0.02 is 92.7% below this industry median. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #15 out of 180 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 42/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #15 out of 180 companies for Debt-to-Equity. This places Scope Fluidics Spolka Akcyjna in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Scope Fluidics Spolka Akcyjna's value of 0.02 is 92.7% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.28, Scope Fluidics Spolka Akcyjna has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.28, based on 180 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scope Fluidics Spolka Akcyjna's current Debt-to-Equity of 0.02 is 92.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scope Fluidics Spolka Akcyjna's current Debt-to-Equity is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł126.08, compared to a current price of zł137.20 — trading 8.8% above its estimated fair value. The current Debt-to-Equity is 0.02, which is 33% below median its 10-year median of 0.03 and 92.7% below the Medical Diagnostics & Research industry median of 0.28. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be overvalued.
The current stock price of zł137.20 is trading 8.8% above its estimated GF Value™ of zł126.08.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
Debt-to-Equity: 0.02 (33% below median its 10-year median of 0.03)
GF Value™: zł126.08 vs. price of zł137.20 (8.8% above fair value)
Industry Position: 92.7% below the Medical Diagnostics & Research median (#15 of 180)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
42GF Score
Get the complete analysis for WAR:SCP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
